Allspring Global Investments Holdings LLC Has $5.56 Million Stake in Sanofi (NASDAQ:SNY)

Allspring Global Investments Holdings LLC grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 128.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 115,330 shares of the company's stock after acquiring an additional 64,747 shares during the period. Allspring Global Investments Holdings LLC's holdings in Sanofi were worth $5,558,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock valued at $8,040,000 after acquiring an additional 33,105 shares in the last quarter. Arkadios Wealth Advisors grew its holdings in Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after purchasing an additional 751 shares during the period. Geode Capital Management LLC grew its holdings in Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. grew its holdings in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after purchasing an additional 399,301 shares during the period. Finally, GFS Advisors LLC grew its holdings in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company's stock worth $738,000 after purchasing an additional 11,655 shares during the period. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded up $0.33 during trading on Friday, reaching $54.46. 1,424,158 shares of the stock were exchanged, compared to its average volume of 2,301,609. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The firm has a market cap of $138.21 billion, a PE ratio of 21.87, a PEG ratio of 1.01 and a beta of 0.57. The stock has a 50-day moving average price of $50.95 and a 200-day moving average price of $52.53. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Ratings Changes

SNY has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi currently has a consensus rating of "Buy" and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.